Lapatinib has been approved for the treatment of breast cancer patients and a phase II clinical trial of lapatinib for the treatment of stage IV melanoma harboring ERBB4 mutations has recently been concluded (NCT01264081). Here, ERBB4 is linked to breast cancer.